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Abstract 
FANCL is the catalytically active component of the 
Fanconi anemia (FA) DNA repair pathway that 
maintains genomic stability by recognizing and 
repairing interstand cross links (ICL), and DNA 
damage incurred during replication.  
The FA pathway is comprised of 22 genes, biallelic 
mutations in any one of these genes causes Fanconi 
anemia, a cancer pre-disposition syndrome 
characterized by chromosomal instability and 
hypersensitivity to DNA crosslinking agents, such as 
those used in chemotherapy like mitomycin C 
(MMC) (Niraj, Färkkilä et al., 2019).   
FANCL acts within the 9 protein FA "core complex" 
(FANCA, FANCG, FAAP20 (AG20), FANCC, 
FANCE, FANCF (CEF), FANCB, FANCL, 
FAAP100 (BL100) that forms in response to DNA 
damage.  Together with E2 conjugating enzyme 
Ube2t (FANCT), the E3 RING ligase FANCL 
monoubiquitinates FANCD2 and FANCI (ID2), this 
signals downstream repair processes, and is 
defective in 95% of all FA patients (Inc, 2014). 
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Identity 
Other names: PHF9, FAAP43, POG 
HGNC (Hugo): FANCL 
Location 
FANCL is located on 2p16.1 which is the short arm 
(p) of chromosome 2 at position 16.1 between base 
pairs 58,159,243 to 58,241,681. 
DNA/RNA 
FANCL has 2 described isoforms produced by 
alternative splicing. Isoform one (Q9NW38-1). Is 
known as the canonical isoform, while isoform 2 
(Q9NW38-2) differs from the canonical sequence at 
178-178: T--> TPQVNS. 
Figure 1:  Genomic context of FANCL on chromosome 2 (Adapted from NCBI). 
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Figure 2:  Exons in FANCL gene. Colour coded to indicate ELF, DRWD, and RING finger domains. Adapted from 
Chandrasekharappa et al. 2013. 
Protein 
Description 
The FANCL gene encodes FANCL protein 
comprised of 375 amino acids with a molecular mass 
of 42905 Da. FANCL is comprised of 3 domains, an 
N-terminal E2-like fold (ELF), a novel double-RWD 
(DRWD) and C-terminal RING domain (Hodson, 
Purkiss et al., 2014). 
Expression 
From total RNA sequencing, FANCL was found to 
be expressed in adrenal gland (RPKM 2.1), prostate 
(RPKM 2.34), thymus (RPKM 2.1), and thyroid 
(RPKM 2.2) (Bioproject PRJNA280600 (PMID 
25970244).  
In another RNA sequencing project on 27 different 
tissues from 95 human individuals, FANCL was 
highly expressed in adrenal gland (RPKM 16.8),  
 
endometrium (RPKM 10.6), lymph nodes (RPKM 
8.5), ovary (RPKM 9.2), prostate (RPKM 8.5), and 
testis (RPKM 12) (Bioproject PRJEB4337, PMID 
24309898). 
Function 
FANCL the catalytically active part of the 9 protein 
Fanconi anemia (FA) core complex comprised of 
FANCB, FAAP100, FANCA, FANCG, FAAP20, 
FANCC, FANCE and FANCF that forms in 
response to DNA damage incurred during DNA 
replication in S-phase, or to detection of interstand 
cross links (ICL) (Ceccaldi, Sarangi et al., 2016). 
FANCL is an E3 ubiquitin ligase that specifically 
monoubiquitinates FANCD2 (at lysine 561) and 
FANCI (at lysine 523) (ID2; Note the FANCD2-
FANCI heterodimer "ID2" must not to be confused 
with the gene ID2) in the presence ofUBE2T 
(FANCT) to signal downstream DNA repair 
proteins. 
 
Figure 3:  A) Schematic of D2 monoubiquitination by E3 RING ligase FANCL and E2 conjugating enzyme. B) Ribbon diagram of 
FANCL with ELF domain (brown), DRWD domain (green), and RING domain (green).  C) Surface representation of protein 
binding domains on FANCL. The binding patch for ubiquitin (orange) is within the ELF domain, while the substrate binding 
domain (red) is in the DRWD domain, and the Ube2t binding domain (light purple) is in the RING domain. Figure from Specificity 
and disease in the ubiquitin system by Viduth K. Chaugule and Helen Walden in Biochemical Society Transactions Feb 2016, 44 
(1) 212-227; DOI: 10.1042/BST20150209. 
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Figure 4:  Schematic of Fanconi Anemia DNA damage response pathway. In response to interstrand cross links (ICL), or DNA 
damage from DNA replication, FANCM recruits the 9 protein core complex to DNA damage sites to monoubiquitinate FANC D2 
and I. The core complex is comprised of 3 sub-complexes AG20 (FANC A, G, FAAP20), BL100 (FANC B, L, FAAP100), and 
CEF (FANC C,E,F).  Dashed lines indicate groupings of sub-complexes, while triple lines indicate putative direct protein 
interactions. Within the core complex, FANCL has a RING E3 domain with ubiquitin ligase activity, but mutation in any one of the 
FA genes leads to defective DNA repair. Ubiquitinated ID2 is activated, and localized to chromatin in nuclear foci to interact with 
downstream DNA repair proteins (FANCD1, FANCD1, FANCN)  to repair DNA via homologous recombination. Once DNA repair 
is completed, USP1 deubiquitinates ID2 so that DNA damage response can be reinitiated. Figure adapted from 
https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/fancb 
 
FANCL is comprised of 3 distinct functional 
domains: the RING domain interacts with the E2 
conjugating enzyme UBE2T (FANCT), the central 
DRWD domain interacts with FANCD2, and the N-
terminal E2-like fold domain (ELF) domain interacts 
with ubiquitin (Hodson et al., 2014, Miles, Frost et 
al., 2015).  
Within the core complex, FANCL interacts as a 
subcomplex with FANCB and FAAP100 (Huang, 
Leung et al., 2014, van Twest, Murphy et al., 2017); 
both proteins stabilize FANCL (Rajendra, 
Oestergaard et al., 2014), and enhance it's activity 5-
fold in vitro assays (Ling, Ishiai et al., 2007).   
Along with FANCA, FANCG, FANCF, FANCL 
was found to interact directly with hairy enhancer of 
split 1 ( HES1), which is a part of the NOTCH1 
developmental pathway involved hematopoietic 
stem cell (HSC) self-renewal (Tremblay, Huang et 
al., 2008).   
Depletion of HES1 from cells resulted in FA-like 
phenotype with disrupted interaction between 
individual core complex proteins, increased cell 
sensitivity to DNA crosslinking agents, and reduced 
MMC-induced ID2 monoubiquitination (Tremblay 
et al., 2008).   
Finally HES1 did not interact FA-mutated core 
complex proteins. HSC defects and eventual bone 
marrow failure in FA patients may be linked to 
inability of HES1 to interact with a defective core 




FANCL-associated Fanconi anemia is inherited in an 
autosomal recessive manner, and accounts for 0.2% 
of all FA cases (Wu, Liu et al., 2017). To date, there 
are only 9 documented cases of FANCL-associated 
FA (Ali, Kirby et al., 2009, Ameziane, Sie et al., 
2012, Chandrasekharappa, Lach et al., 2013, Meetei, 
de Winter et al., 2003, Vetro, Iascone et al., 2015, 
Wu et al., 2017).  
Of the 5 cases with phenotypic and genotypic data, 
four were severe, and one was mild. Two severe 
cases frame shift deletions in exon 4 and 6 that 
truncated FANC, resulted in postnatal mortality and 
presented with VACTERL association (vertebral 
defects, anal atresia, cardiac defects, 
tracheoesophageal fistula, renal malformations, and 
limb defects) (Vetro et al., 2015). Another case with 
homozygous frameshift insertion of exon 9 had a 
severe phenotype with esophageal atresia (Ameziane 
et al., 2012). Finally, a novel homozygous mutation 
c.822_823insCTTTCAGG (p.Asp275LeufsX13) 
had a typical FA presentation with progression to 
bone marrow failture and death at age 9 from acute 
myelomonocytic leukemia (AML-M4) (Wu et al., 






Atlas Genet Cytogenet Oncol Haematol. 2020; 24(5) 192 
 
2017).  The patient with mild FANCL-associated FA 
had bi-allelic mutation (Ali et al., 2009). One allele 
had an in-frame 3-bp deletion c.1007_1009delTAT 
(p.Ile336_Cys337delinsSer) in exon 12 within the 
PHD/RING-finger domain that resulted in loss of 
one amino acid, isoleucine-336, and conversion of 
cysteine-337 to serine null mutation (produces non-
function protein). The other mutated allele had a 4-
bp duplication (c.1095_1098dupAATT 
(p.Thr367AsnfsX13) that resulted in a frameshift 
just outside the RING-finger domain in exon 14. 4-
bp duplication mutation is a hypomorphic mutation 
(produces partially functional protein) (Ali et al., 
2009).  
Sequencing screen of 27 FA cases with unidentified 
mutations uncovered 3 FANCL FA associated 
mutations: c.375-2033C>G (skips exons 4,6,7), 
c.375-2033 C>G (multiple splicing aberrations), 
c.1092G>A (skips exon 13), but didn't have 
corresponding phenotypic data 
(Chandrasekharappa et al., 2013). There is no 
phenotypic data for the first FANCL-associated FA 
patient that had exon 11 deletion and insertion of 




Biallelic mutations in FANCL, or any of the other 21 
FA pathway proteins is implicated in Fanconi 
Anemia (FA), a rare genetic condition that results in 
progressive bone marrow failure (pancytopenia), 
congenital malformations in 75% of patients (short 
stature, urogenital defects, café au lait spots, skeletal 
malformations), and cancer pre-disposition 
(primarily acute myeloid leukaemia, and certain 
solid tumours) (Alter, 2014).   
Mutations that result in loss-of-function of both 
FANCL alleles may correlate with more severe 
phenotypes (Vetro et al., 2015). Hydrocephalus-
VACTERL (vertebral, anal, cardiac, tracheo-
esophageal fistula, renal, and limb anomalies) 
syndrome has been reported in two FANCL-linked 
FA patients that died shortly after birth (Vetro et al., 
2015).  
Prognosis:  The prognosis for FA is poor as there is 
no cure, and the average lifespan is 20-30 years. If 
no congenital abnormalities are apparent at birth, 
patients are often diagnosed with FA when they 
present with aplastic anemia ages 8-10 (>700 fold 
risk) (Alter, 2014). Bone marrow transplants are 
often conducted to correct the haematological issues 
associated with FA, however due to faulty DNA 
repair FA patients retain high cancer risk particularly 
leukaemia, and head and neck squamous cell 
carcinomas (approximately 500 fold risk) 
(Shimamura  Alter, 2010).  
Diagnosis:  Diagnostics for FA is done with a 
chromosomal breakage test; when treated with 
interstand crosslinking agents such as mitomycin C 
(MMC) or diepoxybutane (DEB) FA cells exhibit 
high number chromosomal breakages, and 
abnormalities as compared to normal cells. 
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